CD8A and neoplasm: Inhibiting MGAT1 activity in vivo with compounds like W-GTF01 has demonstrated promising efficacy, particularly in immune-cold TNBC models, by promoting tumor regression through the revival of cytotoxic CD8+ T cell responses.